Aminoglycosides, including gentamicin, amikacin, and tobramycin, are broad-spectrum antibiotics critical for treating multidrug-resistant (MDR) bacterial infections, particularly Gram-negative pathogens like Escherichia coli and Pseudomonas aeruginosa. The market is driven by the global rise of antimicrobial resistance, causing 1.27 million direct deaths annually, and hospital-acquired infections (HAIs), affecting 7-15% of inpatients. Aminoglycosides are vital for MDR tuberculosis (530,000 cases in 2022) and cystic fibrosis lung infections. Inhaled tobramycin and streptomycin’s inclusion in WHO’s Essential Medicines List boost demand. The global aminoglycosides market is estimated at USD 1.0-2.0 billion in 2025, with a CAGR of 3%-7% through 2030.
This product will be delivered within 1-3 business days.
Regional Market Trends
- North America: The U.S. leads with advanced ICU care for HAIs, while Canada focuses on cystic fibrosis treatments.
- Europe: Germany, France, and the UK drive growth with robust infection control programs.
- Asia Pacific: China and India see rising demand due to high MDR burden, with Japan emphasizing tuberculosis care.
- Rest of the World: Africa prioritizes MDR-TB treatment, while Latin America addresses HAIs.
Application Analysis
- Veterinary: Expected growth of 3.2%-7.2%, driven by livestock infections. Trends focus on regulated use.
- Skin Infection: Projected growth of 3.0%-7.0%, linked to topical formulations. Advances emphasize combination therapies.
- Respiratory Diseases: Anticipated growth of 3.5%-7.5%, tied to cystic fibrosis. Trends highlight inhaled therapies.
- UTI & Pelvic Diseases: Expected growth of 3.3%-7.3%, suited for Gram-negative infections. Developments prioritize hospital use.
- Other Diseases: Expected growth of 2.8%-6.8%, covering sepsis. Trends focus on combination regimens.
Type Analysis
- Neomycin: Expected growth of 2.8%-6.8%, valued for topical use. Trends focus on OTC formulations.
- Tobramycin: Projected growth of 3.5%-7.5%, favored for cystic fibrosis. Advances emphasize inhaled delivery.
- Gentamicin: Anticipated growth of 3.2%-7.2%, critical for HAIs. Trends highlight combination therapies.
- Amikacin: Expected growth of 3.4%-7.4%, suited for MDR infections. Developments prioritize IV formulations.
- Paromomycin: Expected growth of 2.7%-6.7%, used for parasitic infections. Trends focus on niche indications.
- Streptomycin: Expected growth of 3.3%-7.3%, vital for MDR-TB. Trends highlight WHO guidelines.
- Kanamycin: Expected growth of 2.9%-6.9%, used in resistant infections. Developments prioritize generics.
- Others: Expected growth of 2.6%-6.6%, covering novel analogs. Trends focus on resistance mitigation.
Key Market Players
- Pfizer: Offers gentamicin for hospital infections.
- Teva Pharmaceutical: Supplies affordable aminoglycosides.
- AbbVie: Provides tobramycin for cystic fibrosis.
- Merck: Develops amikacin formulations.
- Cipla Limited: Focuses on generics for MDR-TB.
Porter’s Five Forces Analysis
- Threat of New Entrants: Low, due to complex manufacturing and regulatory barriers.
- Threat of Substitutes: Moderate, with newer antibiotics competing, but aminoglycosides remain essential for MDR.
- Bargaining Power of Buyers: High, as generics increase price competition.
- Bargaining Power of Suppliers: Low, with multiple API providers.
- Competitive Rivalry: High, with generic manufacturers competing on price.
Market Opportunities and Challenges
Opportunities:
- Addressing MDR infections, causing 1.27 million deaths annually.
- Managing HAIs, affecting 7-15% of inpatients.
- Leveraging WHO guidelines for MDR-TB treatment.
- Utilizing inhaled tobramycin for cystic fibrosis.
- Supporting infection control in high-burden regions.
- Meeting demand from rising MDR prevalence.
Challenges:
- Toxicity risks like nephrotoxicity requiring monitoring.
- Competition from newer antibiotics.
- Regulatory delays for novel formulations.
- Price erosion due to generics.
- Limited access in low-income regions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Historical and Forecast Aminoglycosides Market in North America (2020-2030)
Chapter 9 Historical and Forecast Aminoglycosides Market in South America (2020-2030)
Chapter 10 Historical and Forecast Aminoglycosides Market in Asia & Pacific (2020-2030)
Chapter 11 Historical and Forecast Aminoglycosides Market in Europe (2020-2030)
Chapter 12 Historical and Forecast Aminoglycosides Market in MEA (2020-2030)
Chapter 13 Summary For Global Aminoglycosides Market (2020-2025)
Chapter 14 Global Aminoglycosides Market Forecast (2025-2030)
Chapter 15 Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- Pfizer
- Teva Pharmaceutical
- AbbVie
- Merck
- Cipla Limited
- Viatris
- Sun Pharmaceutical
- Aurobindo Pharma
- Lupin Limited
- Fresenius Kabi